- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 09.07. | Roche scraps two Ionis-partnered Huntington's drugs | ||
| 09.07. | GSK ends brain drug alliance with Alector | ||
| 09.07. | HHS plan to speed drug research won't remove 'self-inflicted' delays | ||
| 09.07. | AstraZeneca, Ionis drug fails big heart disease study in major setback | ||
| 08.07. | AstraZeneca, GSK intensify China ties with Sino Biopharm deals | ||
| 08.07. | Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal | ||
| 07.07. | Oberland pours up to $400M into MeiraGTx eye gene therapies | ||
| 07.07. | Kailera says obesity pill succeeds in late-stage trial in China | ||
| 07.07. | Vertex to acquire Crinetics in $10B foray into endocrine disease drugs | ||
| 06.07. | Gene editing developer Scribe plots an IPO | ||
| 06.07. | Novartis to acquire ADC developer in a deal worth up to $1.5B | ||
| 06.07. | Beyond Boston: Unlikely cities stake biotech claims | ||
| 06.07. | Cancer, immune drugmakers dominate VC funding so far in 2026 | ||
| 02.07. | A PureTech startup banks $180M for a new IPF drug | ||
| 02.07. | Roche KRAS drug succeeds in head-to-head lung cancer study | ||
| 01.07. | Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal | ||
| 30.06. | Ipsen's $450M blood cancer drug; FDA selects first cohort for "pre-check" pilot program | ||
| 30.06. | Viridian may have edge over Amgen in eye drug showdown, analysts argue | ||
| 30.06. | Beeline ups its Series A round for immune drug work | ||
| 29.06. | Theravance, after clinical setbacks, agrees to $929M buyout | ||
| 29.06. | 10 clinical trials to watch in the second half of 2026 | ||
| 26.06. | FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services | ||
| 26.06. | At BIO, tension over China biotech deal regulation looms | ||
| 26.06. | Alkermes' incoming CEO has a plan to outplay Lilly and Takeda | ||
| 26.06. | On second try, Acadia drug gets nod from European regulators |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.